Dexelvucitabine

This article does not cite any sources. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (March 2015) (Learn how and when to remove this template message)

Dexelvucitabine

Names
Preferred IUPAC name 4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-1-yl]pyrimidin-2(1H)-one
Other names Reverset
Identifiers
CAS Number	134379-77-4 Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL109831 N
ChemSpider	58498 N
KEGG	D03981 Y
PubChem CID	64973
UNII	KU8SPJ271W Y
CompTox Dashboard (EPA)	DTXSID20158678
show InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 N Key: HSBKFSPNDWWPSL-CAHLUQPWSA-N N InChI=1/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 Key: HSBKFSPNDWWPSL-CAHLUQPWBD
show SMILES F\C1=C\N(C(=O)\N=C1\N)[C@@H]/2O[C@@H](\C=C\2)CO
Properties
Chemical formula	C9H10FN3O3
Molar mass	227.195 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Dexelvucitabine is a failed experimental agent for the management of HIV infection. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.^{[medical citation needed]}

On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme, lipase) in a phase II trial.^{[citation needed]}

This antiinfective drug article is a stub. You can help Wikipedia by .

• v
• t